July 31, 2014 11:26 PM ET


Company Overview of Fermavir Pharmaceuticals, Inc.

Company Overview

FermaVir Pharmaceuticals, Inc., a development stage biotechnology company, holds licensed patents for a series of compounds for the treatment of viral diseases in the United States. It has patents for compounds for the treatment of varicella zoster virus (VZV), the causative agent for shingles and chickenpox, as well as human cytomegalovirus, which includes the viruses that cause chicken pox, mononucleosis, herpes labialis, and genitalis. The company is conducting preclinical trials on FV-100, a prodrug of a compound CF-1743, for the treatment of shingles. In addition, FermaVir Pharmaceuticals intends to identify a clinical candidate for the treatment of CMV infections in transplant patients...

420 Lexington Avenue

Suite 445

New York, NY 10170

United States

1 Employees



Key Executives for Fermavir Pharmaceuticals, Inc.

Chief Executive Officer
Age: 66
Founder and Director
Age: 72
Compensation as of Fiscal Year 2014.

Similar Private Companies By Industry

Company Name Region
SironRX Therapeutics, Inc. United States
Avidia, Inc. United States
UVL Blood Labs, Inc. United States
Radix Bio Solutions Ltd. United States
HK Pharmaceuticals Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Fermavir Pharmaceuticals, Inc., please visit www.fermavir.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.